Causality assessment in pharmacovigilance in 2026: Inspection Logic and Regulatory Expectations
February 27, 2026
This article explains how regulators evaluate adverse event assessment methods in pharmacovigilance inspections, why weak safety case assessment leads to repeat findings, and how structured causality analysis strengthens signal detection decision making and benefit–risk evaluation under regulatory review.
